Author: admin

Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Clostridium Difficile Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Clostridium Difficile Infections Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Clostridium Difficile Infections Pipeline Outlook Report

Key Takeaways from the Clostridium Difficile Infections Pipeline Report

  • In June 2025, Vedanta Biosciences Inc. announced a study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
  • In June 2025, Crestone Inc. announced a research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.
  • DelveInsight’s Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.
  • The leading Clostridium Difficile Infections Companies such as Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
  • Promising Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.

Discover how the Clostridium Difficile Infections treatment paradigm is evolving. Access DelveInsight’s in-depth Clostridium Difficile Infections Pipeline Analysis for a closer look at promising breakthroughs @ Clostridium Difficile Infections Clinical Trials and Studies

Clostridium Difficile Infections Emerging Drugs Profile

  • VE303: Vedanta Biosciences

VE303 is a potential first-in-class live biotherapeutic product candidate being developed by Vedanta Biosciences to prevent recurrence of Clostridioides difficile infection (CDI). It consists of a rationally-designed, defined bacterial consortium of 8 strains of clonal human commensal bacteria selected for their ability to provide colonization resistance to C. difficile. VE303 is administered orally in capsules and is produced under CGMP conditions from pure, clonal bacterial cell banks, yielding a standardized drug product. In a Phase II study, high-dose VE303 met its primary endpoint of preventing CDI recurrence at eight weeks in patients at high risk of recurrence. VE303 was generally well-tolerated in the study. Vedanta is currently enrolling patients into a pivotal Phase III registrational study called RESTORATiVE303 to evaluate the efficacy and safety of VE303 for the prevention of recurrent CD.

  • Ibezapolstat: Acurx Pharmaceuticals

Ibezapolstat (formerly named ACX-362E) is our lead antibiotic candidate. Ibezapolstat is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI. In June 2018, ibezapolstat was designated by the US Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted Fast Track designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. Currently, the drug is in the Phase II stage of its development for the treatment of Clostridium Difficile Infections.

The Clostridium Difficile Infections Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
  • Clostridium Difficile Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market

Explore groundbreaking therapies and clinical trials in the Clostridium Difficile Infections Pipeline. Access DelveInsight’s detailed report now! @ New Clostridium Difficile Infections Drugs

Clostridium Difficile Infections Companies

Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.

Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Clostridium Difficile Infections Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Clostridium Difficile Infections Market Drivers and Barriers, and Future Perspectives

Scope of the Clostridium Difficile Infections Pipeline Report

  • Coverage- Global
  • Clostridium Difficile Infections Companies- Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
  • Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
  • Clostridium Difficile Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Clostridium Difficile Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Clostridium Difficile Infections drug development? Find out in DelveInsight’s exclusive Clostridium Difficile Infections Pipeline Report—access it now! @ Clostridium Difficile Infections Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Clostridium Difficile Infections: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Clostridium Difficile Infections– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. VE303: Vedanta Biosciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ibezapolstat: Acurx Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Clostridium Difficile Infections Key Companies
  21. Clostridium Difficile Infections Key Products
  22. Clostridium Difficile Infections- Unmet Needs
  23. Clostridium Difficile Infections- Market Drivers and Barriers
  24. Clostridium Difficile Infections- Future Perspectives and Conclusion
  25. Clostridium Difficile Infections Analyst Views
  26. Clostridium Difficile Infections Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

JC Tires Mobile 24/7 LLC Announces Expansion of Tire Services Across Southern Arizona

JC Tires Mobile 24/7 LLC to expand its tire services to new areas, including Marana, Red Rock, Vail, Sahuarita, Green Valley, Benson, Willcox, Nogales, and Oro Valley.

JC Tires Mobile 24/7 LLC, a leading mobile tire service provider based in Tucson, has announced the expansion of its 24/7 mobile tire services to new areas across Southern Arizona. The company will now offer services in Marana, Red Rock, Vail, Sahuarita, Green Valley, Benson, Willcox, Nogales, and Oro Valley.

“We are delighted to announce the expansion of our mobile tire services to newer areas across Southern Arizona,” says the spokesperson for JC Tires Mobile 24/7. “This strategic move will help us extend reliable tire support to customers in more remote and underserved locations. It marks a significant milestone and strengthens our commitment to delivering fast, affordable, and professional tire services directly to the customer’s location.”

The company’s reputation has been built on consistent customer satisfaction, prompt response times, and an unwavering focus on safety and convenience.

With the latest addition of service areas, JC Tires is now accessible to a broader base of vehicle owners, fleet managers, and trucking companies needing on-the-spot tire replacement and roadside assistance.

For those managing commercial fleets or operating heavy-duty equipment, access to reliable tire service is crucial for maintaining productivity. Until now, many newly covered areas had limited access to dependable, on-demand tire support. This situation forced customers to rely on tow trucks, endure long delays at service shops, or deal with unscheduled downtime, resulting in the loss of time and money.

JC Tires Mobile 24/7 LLC addresses these challenges by providing a mobile solution that arrives at the customer’s location, whether on the roadside, at a business facility, or in a residential driveway.

The company offers on-site tire services, including sales, installation, and repair for semi-trucks, trailers, heavy equipment, and standard commercial vehicles. The services are performed by trained technicians who ensure proper installation and performance while prioritizing safety.

Whether a flat tire on a semi-truck or a full replacement for heavy equipment, JC Tires provides quick turnaround times without needing towing or shop visits.

This expansion is expected to reduce downtime for customers operating in outlying communities significantly. It also enhances regional safety by ensuring that tire emergencies can be addressed swiftly, especially in areas where traditional tire shops are scarce or distant.

JC Tires Mobile 24/7 LLC has become a trusted partner for countless drivers and businesses across the Tucson region. Known for its 24/7 availability, the company offers immediate roadside assistance for trucks and commercial vehicles. Prompt response to calls and technical expertise reinforce its position as a go-to mobile tire service provider in Southern Arizona.

By expanding its footprint, JC Tires Mobile 24/7 LLC reaffirms its mission to keep Arizona drivers moving safely and efficiently. From flat tires to full replacements, the company can respond swiftly and professionally at any hour, in any location within its growing service area.

For more information, visit https://jctiresmobile.com.

About JC Tires Mobile 24/7 LLC

JC Tires Mobile 24/7 LLC is a mobile tire service company based in Tucson, AZ. It offers 24/7 on-site tire sales and installations for semi-trucks, trailers, and heavy equipment. They provide fast, professional, and affordable tire solutions delivered directly to your location, whether the customer is stuck on the road, at home, or at your business.

Media Contact
Company Name: JC TIRES MOBILE 24/7 LLC
Contact Person: Jose Castillo
Email: Send Email
Phone: 5202600779
Address:7090 N Oracle Road #178
City: Tucson
State: AZ
Country: United States
Website: https://www.jctiresmobile.com/

A Family’s Health Crisis Sparks a Cleaner, Healthier Way Forward for Homes Everywhere

How Personal Struggles with Chronic Illness Inspired the Mission Behind Ecolosophy

Some companies are born in boardrooms. Ecolosophy was born in hospital rooms, doctor’s offices, and long nights spent searching for answers. For John Vargas, co-founder of Ecolosophy, what began as a desperate attempt to save his wife’s life became a broader mission to change how we think about our homes and health.

A JOURNEY FROM PERSONAL CHALLENGE TO PURPOSE

“My wife Cynthia went through a long period of unexplained illness that nearly took her life,” John shares. “We tried everything — changing diets, medications — but nothing worked. It wasn’t until a doctor pointed out that it’s not just what you put in your body, but what you surround yourself with, that we started looking closer at the everyday products in our home.”

That shift in perspective, guided by environmental health experts like Dr. Leon Mellman, revealed what they hadn’t seen before: ordinary household products filled with ingredients that could be undermining health, especially for those already vulnerable. It became clear that the very things meant to keep homes clean were introducing invisible risks.

This realization planted the seeds for Ecolosophy — a company focused on creating cleaning products that are truly safe for people and the planet.

BUILDING SOMETHING BETTER

John wasn’t alone in this journey. Italo Campilii, a longtime friend and entrepreneur who had battled Crohn’s disease for decades, had made his own discovery: eliminating environmental toxins led to a dramatic improvement in his health.

“When we saw the difference it made, we couldn’t unsee it,” John says. “We realized the products so many families use every day weren’t just unnecessary — they were harmful. We felt a responsibility to offer a better option.”

Drawing on years of experience in business and technology, John helped bring together a small but determined group of founders: Elizabeth Uría, as a STEM mom and scientist, an expert in environmental toxicology; Miguel Valdivia, an entrepreneur with over 25 years in manufacturing and the chemical industry, and an innovator in sustainable product development; and Italo Campilii, whose personal health journey fueled the company’s vision for healthier homes.

“I’m incredibly proud to offer families a plant-based, non-toxic formula made from just nine ingredients you can recognize and pronounce—especially knowing it’s safe to use around our children,” Elizabeth says. “It’s a relief to finally have a cleaning product that aligns with my values and gives parents peace of mind. And seeing the first person with a chronic illness and their family experience dramatic improvements in their quality of life after using our concentrate for a year was the moment I knew we were truly making a difference.”

“After living with Crohn’s for over two decades, I committed to a full detox—removing pesticides, fragrances, and every artificial substance from my home, while elevating my daily routines to focus on clean air, pure water, and nourishing habits. The moment I swapped out toxic cleaners for Ecolosophy’s concentrate, I felt a shift in my well-being I hadn’t experienced since I was a teenager. It’s not just about having a clean house; it’s about creating an environment where families can thrive, free from the hidden chemicals that hold us back. I’m truly passionate about this mission because I know firsthand how environmental toxins can devastate health and the pain families endure watching their loved ones suffer. We want to spread this message far and wide—and we need help to do it.”Italo says

Together, they started Ecolosophy not as a trend, but as a necessity — offering real solutions for families seeking healthier environments.

INNOVATION ROOTED IN REAL LIFE

Ecolosophy’s flagship product — a highly concentrated, multi-use cleaner — isn’t just convenient or eco-friendly. It’s the result of years of research into how everyday chemicals impact health. The concentrate can be diluted to create nine different cleaning solutions, reducing the need for dozens of single-use plastic bottles and cutting household chemical exposure dramatically.

“We didn’t set out to create just another ‘green’ product,” John explains. “We wanted to rethink the whole model — fewer products, fewer toxins, less waste.”

The company’s approach aligns with growing awareness around environmental wellness — the understanding that our surroundings are a critical part of our overall health — and the circular economy, a model aimed at minimizing waste and maximizing sustainability.

REDEFINING CLEAN FOR HEALTHIER LIVING

For too long, the home care industry has pushed the idea that cleaning means strong chemicals and countless specialized products. Ecolosophy challenges that assumption by offering a simpler, safer alternative — one that protects families while respecting the planet.

“Our mission is to make it easier for people to live healthier lives without adding more complexity,” John says. “One high-performing concentrate can replace most of the bottles cluttering the typical home, and do it without harsh chemicals.”

Today, Ecolosophy is seeing strong growth fueled by consumers who are increasingly aware of how their environments impact their well-being — and who are seeking trustworthy, effective solutions.

LOOKING AHEAD: WELLNESS BEYOND CLEANING

Ecolosophy’s mission doesn’t stop at cleaning products. The team is already looking toward new ways to reduce environmental triggers in the home, from improving air and water quality to offering education that empowers families to make informed choices.

“Good health starts at home,” John says. “We want to be part of a movement that helps people see their homes not just as places to live, but as environments that can either support or undermine their well-being.”

See Ecolosophy’s growing lineup of science-backed cleaning solutions by visiting https://ecolosophy.com/.

ABOUT THE FOUNDERS

John Vargas brings over 31 years (25 years at Apple, Inc.) of leadership experience in technology and business innovation to Ecolosophy, shaped by his personal journey navigating a family health crisis. He is joined by Elizabeth Uría, as a STEM mom and scientist and expert in environmental toxicology; Miguel Valdivia, an entrepreneur with over 25 years in manufacturing and the chemical industry and a leader in eco-friendly product development; and Italo Campilii, a longtime entrepreneur whose personal battle with chronic illness sparked a passion for cleaner living. Together, they are redefining what it means to create products that are safe, sustainable, and rooted in real-world needs.

ABOUT ECOLOSOPHY

Ecolosophy creates science-backed cleaning solutions designed to remove hidden environmental triggers from homes. Committed to environmental wellness and sustainability, the company’s mission is to empower families to create healthier living spaces with fewer chemicals and less waste — all while supporting the planet for future generations. Explore Ecolosophy’s products now by visiting https://ecolosophy.com/.

Note: Ecolosophy products support the body’s natural processes by reducing environmental stressors but are not intended to diagnose, treat, cure, or prevent any disease.

Follow on social media:

Facebook: @JoinEcolosophy

Instagram: @joinecolosophy

TikTok: @ecolosophy

Twitter/X: @JoinEcolosophy

Pinterest: @JoinEcolosophy

Media Contact
Company Name: Ecolosophy
Contact Person: Italo Campilii
Email: Send Email
City: HOUSTON
State: TEXAS
Country: United States
Website: https://ecolosophy.com/

Hulkman Alpha Pro Jump Starter Reliability Safety Everyday Guardian

As a pioneer in this industry, Hulkamn was created by a group of ambitious and dedicated entrepreneurs with a vision to redefine the automotive & energy industry. They recruited high experienced talent around the world to create automotive & energy products and services that delight their consumers.

Hulkman, launched its new Jump Starter Alpha Pro Series, today unveils a game-changer for American drivers: engineered to dominate roadside emergencies across America. With three peak-power variants (1500A, 1750A, 2000A), the Alpha Pro combines Hulk-like strength with military-grade protection, redefining reliability for trucks, RVs, and daily drivers.

Unmatched Power When Stranded:

For millions of Americans, a dead car battery isn’t just an inconvenience; it’s being stranded in a parking lot after dark, missing a critical appointment, or facing a potential safety hazard on a lonely road. While jumper packs are common, a new standard is emerging, prioritizing not just starting power, but comprehensive safety, intuitive use, and rugged reliability. Enter the Hulkman Alpha Pro, engineered to be more than just a jump starter – it’s a vital layer of preparedness for the modern driver.

From Ford F-150s to Tesla Cybertrucks, the Alpha Pro delivers raw starting power engineered for real-world extremes.True 1500A/1750A/2000A CRANKING POWER: Proprietary clamps deliver lab-verified current even at -20°F (Montana winters) or 122°F (Arizona summers). Imagine a frigid morning or a remote highway – your battery’s dead. The Alpha Pro Jump Starter delivers a staggering 2000A of peak current, capable of jump-starting everything from compact sedans to heavy-duty pickup trucks (8.5L gasoline / 6.0L diesel engines). Its 74Wh high-density battery ensures multiple starts on a single charge, banishing roadside anxiety.

The Unpredictable Road: Why Basic Isn’t Enough Anymore

Imagine a frigid Midwest morning. Frost coats the windshield, and your sedan refuses to crank. A standard jump pack might help, but what if the clamps spark dangerously in the dim garage light? Or worse, what if you accidentally connect them backward in the cold-induced hurry, risking damage or fire? The Hulkman Alpha Pro addresses these real-world risks head-on. Its Built-in Safety Suite features Spark-Free Technology and Reverse Polarity Protection with Audible & Visual Alerts, physically preventing dangerous connections and clearly warning users of mistakes – a critical safeguard for every driver, especially those less familiar with car mechanics. Protected copper bars ensure clamps won’t accidentally short, preventing burns, while a loud 60dB Alarm System warns of critical issues like extreme temperatures or low power.

Power When You Need It, Intelligence to Guide You

Stranded with a completely dead battery? The Boost Mode cuts through the anxiety, delivering the necessary surge to revive even a “death battery.” The large, 3.3-inch Smart Display acts as your co-pilot, going beyond a simple “ready” light. It provides Clear Error Codes (like “Error 2” for car battery is weak or nearly dead or “Error 3” for Jump Starter is inoperable due to extreme temperatures) and actionable Safety Guidance, diagnosing why the car might not start before you attempt the jump, preventing frustration and potential damage. This intelligence empowers users, making a stressful situation manageable.

Beyond the Jump: Your Onboard Power Hub

Modern vehicles are rolling tech hubs. The Hulkman Alpha Pro recognizes this, featuring a 65W USB-C Fast Charging Port capable of charging laptops, tablets, or phones at high speed – perfect for keeping essential devices powered during roadside waits or while working remotely from your vehicle. 65W USB-C PD FAST CHARGE: 0→100% in 50 minutes – faster than most smartphones. Its 150W MAX DC Output (15V/10A) pushes the boundaries, reliably powering larger devices like portable coolers, inflators, or even CPAP machines during camping trips or unexpected outages, extending the utility far beyond emergency jumps. The substantial 74Wh High-Density Battery ensures multiple jump starts or extended device charging, offering genuine peace of mind for longer trips or repeated needs.

Built for the Real World: Ruggedness Meets Refinement

American life demands durability. The Hulkman Alpha Pro delivers with Military-Grade Toughness: a Dual-Material Shock-Resistant Shell combining hard plastic and soft rubber over-mold for maximum impact and drop protection. Critical ports feature IP65-Rated Sealed Covers when closed, guarding against dust and water spray common on job sites or muddy tailgates. Crucially, the casing utilizes UL 94V-0 Fire-Retardant Materials – meeting stringent safety standards for flammability. Ergonomic, Curved Clamps require significantly less force to attach securely, even with cold or gloved hands, making the process easier and safer. Attention to detail extends to the packaging, reflecting the product’s quality.

A Vital Companion for Every Journey

The Hulkman Alpha Pro isn’t just about starting your car; it’s about mitigating risk, providing essential power, and offering clarity in stressful situations. It represents a shift towards intelligent, safety-first preparedness for the American driver – whether navigating the daily commute, embarking on a cross-country road trip, or simply ensuring family safety during winter errands. By integrating robust power, unparalleled safety features, intuitive diagnostics, and rugged construction, it sets a new benchmark for what a vehicle power solution should be.

Grab yours today and drive with confidence, wherever the road takes you. Visit Hulkman Amazon to learn more.

Media Contact
Company Name: Hulkman LLC
Contact Person: Frank LI
Email: Send Email
Country: United States
Website: hulkman.com

Prime Sports Institute Transforms the Landscape of Health and Performance in Bellingham, WA

Prime Sports Institute is setting a new standard in integrative health and athletic performance in the Pacific Northwest. Located in the heart of Bellingham, Prime offers a science-backed, team-based approach to health optimization for athletes, active individuals, and anyone seeking to move and feel better.

Founded with a mission to empower people to live pain-free, perform at their peak, and achieve lifelong wellness, Prime provides an innovative blend of services under one roof. From athletic training and physical therapy to nutrition counseling, strength and conditioning, and Bellingham massage, Prime’s multidisciplinary team works collaboratively to deliver customized care plans based on individual goals and needs.

“Our approach is different because we focus on the whole person, not just the injury or symptom,” says the Prime team. “Whether you’re a weekend warrior, professional athlete, or recovering from surgery, our goal is to help you move well, recover faster, and stay strong—long-term.”

A One-Stop Hub for Performance and Recovery

Prime Sports Institute is more than just a gym or physical therapy clinic—it’s a comprehensive resource for sustainable health. The facility is equipped with state-of-the-art tools and spaces to support recovery, mobility, and strength development, including:

  • Athletic Training tailored to sport-specific performance

  • Sports Massage Therapy to relieve tension and improve circulation

  • Strength & Conditioning programs focused on safe progression

  • Physical Therapy rooted in functional movement science

  • Nutrition Services to fuel performance and recovery

Prime is especially known for bridging the gap between rehabilitation and performance. Patients often transition from physical therapy into training programs that not only maintain recovery but build long-term resilience.

Community-Focused, Athlete-Tested

With deep roots in Bellingham’s active outdoor and athletic community, Prime serves a diverse clientele—from cyclists and runners to skiers, climbers, and youth sports athletes. The team takes pride in fostering a welcoming environment for people of all ages and fitness levels.

Through educational workshops, personalized coaching, and injury prevention strategies, Prime equips clients with the knowledge and tools they need to take ownership of their health.

“Our clients don’t just come to us with a problem—they leave with a plan and a team behind them,” the team emphasizes.

Learn More

To learn more about Prime Sports Institute’s full suite of services or to book an appointment, visit www.primebellingham.com. Whether you’re recovering, training, or simply wanting to feel your best every day, Prime is here to support your journey toward optimal health and performance.

Media Contact
Company Name: Prime Sports Institute
Contact Person: Kerry Gustafson
Email: Send Email
Country: United States
Website: https://www.primebellingham.com

Trex Group Expands Freight Services Across U.S., Canada, and Mexico

Trex Group Expands Premier Freight Shipping Services Across U.S., Canada, and Mexico — Setting the Gold Standard in Logistics.

Miami, FL, USA – June 25, 2025 – Trex Group, a leader in North American logistics and transportation, proudly announces the expansion of its nationwide freight shipping operations, now offering streamlined service coverage across the United States, Canada, and Mexico. With over two decades of experience in the transportation industry, Trex Group continues to set the standard in LTL freight, full truckload (FTL), partial shipments, and expedited shipping solutions.

Headquartered in Miami, Florida, Trex Group has earned a reputation as one of the most trusted freight service providers, combining cutting-edge technology, dedicated logistics experts, and a deep commitment to customer satisfaction. From small business shippers to Fortune 500 enterprises, Trex Group ensures every load moves with precision, transparency, and speed.

“At Trex Group, your cargo is our priority — always,” said a spokesperson for the company. “We don’t just deliver freight; we deliver peace of mind.”

Full Spectrum Freight Solutions Tailored for Modern Logistics

Trex Group offers a robust suite of freight solutions to meet the needs of businesses of all sizes:

• LTL Services – Reliable Less Than Truckload shipping across the U.S., with advanced tracking and flexible scheduling.

• Full Truckload Services – Maximize capacity and efficiency with FTL options designed for time-sensitive, high-volume shipments.

• Partial Shipment Services – Ideal for businesses seeking cost-effective alternatives to FTL without sacrificing delivery speed.

• Expedited Freight Service – When speed is critical, Trex delivers with same-day and next-day solutions across North America.

• Request a Freight Quote – Get a fast, free freight quote online with zero commitment.

20+ Years of Freight Expertise — Now Even Stronger

With more than 20 years of hands-on industry experience, Trex Group has navigated every kind of shipping challenge, earning accolades for reliability, punctuality, and service excellence. The company’s cross-border expertise ensures seamless freight movement to and from Canada and Mexico, managing customs, documentation, and last-mile delivery.

Tech-Driven & Client-Focused

Trex Group is known for leveraging the latest transportation management systems (TMS) to optimize routes, reduce transit time, and improve cost efficiency. Their customer portal offers real-time tracking, digital document access, and proactive communication from pickup to drop-off.

Trex Group – Corporate HQ

Miami, FL

Phone: 786-325-0547

Email: quotes@trexshipping.com

Website: www.trexshipping.com

About Trex Group

Trex Group is a logistics powerhouse based in Miami, Florida, offering full-scale freight transportation services with a reach across the U.S., Canada, and Mexico. Specializing in LTL, FTL, expedited, and partial truckload shipping, Trex Group is committed to delivering your cargo with speed, security, and exceptional service. Trusted by thousands of clients nationwide, Trex Group is more than a carrier — it’s a freight partner for your business growth.

Media Contact
Company Name: Trex Group
Contact Person: Media Relations
Email: Send Email
Phone: 786-325-0547
Country: United States
Website: https://trexshipping.com

CD BioSciences Releases Multi-Omics Analysis Services to Accelerate Aging Research

New York, USA – June 25, 2025 – CD BioSciences, the leading provider of innovative services and solutions in life sciences, announced multi-omics analysis services to expedite aging research. Using different omics technologies including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, CD BioSciences offers a broad scope of coverage into the biology of aging.

“Systems biology is needed to understand the molecular basis of aging,” stated the business development manager of CD BioSciences. “Our multi-omics analysis service allows researchers to discover challenging insights into longevity, cellular senescence, and age-associated diseases, greatly expedite the process of anti-aging intervention.”

Why do omics studies matter in aging research?

Recent advances in high-throughput technologies have enabled omics studies, opening new pathways to understanding the mechanisms of aging and the progression of complex age-related diseases. Multiple biological layers—including the genome, transcriptome, proteome, and metabolome—interact dynamically during aging to regulate and carry out biological functions. Scientists are increasingly relying on multi-omics approaches to uncover biomarkers, pathways, and therapeutic targets associated with aging and age-related diseases.

The multi-omics analysis services at CD BioSciences can provide an all-inclusive package, from the experiment design and data generation, to the in-depth bioinformatics analysis, allowing scientists to unravel intricate interactions that contribute to aging processes. Given that it’s difficult for single omics to provide a comprehensive understanding of the biological mechanisms of aging and disease, at CD BioSciences, multiple omics approaches (e.g., genomics, transcriptomics, proteomics, immunomics, metabolomics, epigenomics, single-cell omics, and spatial omics) are integrated to cover various biological information at different scales including genetic variations, gene expression patterns, protein abundance, metabolite profiles, epigenetic modifications, and so on! Based on the multi-omics aging biomarker services, CD BioSciences have discovered sets of biomarkers related to aging. Such biomarkers might be indicative for biological age and therefore be of great interest to reveal the course of aging.

To better understand the molecular mechanisms of aging, CD BioSciences also offers a comprehensive range of multi-omics aging clock development solutions. These clocks will provide a quantitative measure of biological age, offer insights into the underlying molecular processes associated with aging, and assist in the discovery and development of novel therapeutics targeting age-related diseases.

CD BioSciences’ multi-omics analysis services are particularly valuable for academic institutions, pharmaceutical companies, and biotech firms focused on geroscience, longevity research, and precision medicine. By integrating multi-omics data, researchers can identify potential therapeutic targets, validate aging biomarkers, and develop predictive models for aging trajectories.

About CD BioSciences

CD BioSciences is a research service provider specializing in aging research. It offers a comprehensive range of services, encompassing research on aging mechanisms, preclinical drug discovery and development, and the development of healthcare and skincare products. With a team of experienced scientists and advanced facilities, CD BioSciences is committed to advancing the understanding of aging and developing innovative solutions to promote healthy aging.

Follow Us on: Facebook | Twitter | LinkedIn

Media Contact
Company Name: CD BioSciences
Contact Person: Kikiwi Davis
Email: Send Email
Phone: 1-315-636-4280
Country: United States
Website: https://www.agingclocks.com

Logistics Talent Agency: North America’s Go-To Experts in Logistics & Supply Chain Recruitment

As freight volatility and tariff shifts intensify, Logistics Talent Agency is helping companies across North America stay competitive by headhunting logistics professionals who deliver real-world impact in real-time operations.

In today’s economy, logistics is no longer just a function. It is a battleground. From skyrocketing freight rates to tariff turbulence and sudden supply chain reroutes, North American companies are operating in a system that is more complex, more regulated, and more unpredictable than ever. The stakes are higher than most realize.

Freight volatility and tariff pressure are fundamentally transforming the landscape of the continent. The Globe and Mail sits down with Eden Mordchaev, CEO of Logistics Talent Agency, to learn how the firm is helping companies stay ahead by recruiting the people who know how to move things forward.

As organizations scramble to adapt, one truth is becoming increasingly clear: the companies that win are the ones with the right logistics teams in place. Not just software. Not just strategies. The actual people making the real-time decisions that shape margins, mitigate risks, and drive competitive edge.

That’s where Logistics Talent Agency, based in Austin, Texas, with offices in Toronto, is making an outsized impact. In our recent interview with the firm’s founder and CEO, Eden Mordchaev, he shared how his team has become a trusted logistics recruitment agency for manufacturers, 3PLs, food importers, ecommerce retailers, and customs brokers across the United States, Canada, and Mexico, recruiting the supply chain professionals who don’t just keep operations running, but who actively reduce cost, increase speed, and improve resilience.

“You can build the best product in the world, but if your freight is stuck, your customs filings are wrong, or your warehouse cannot keep up, none of it matters,” Mordchaev told The Globe and Mail. “In today’s economy, your logistics team is your business.”

Logistics is Now a Boardroom Issue

Over the past several years, logistics has shifted from a back-office function to a board-level priority. Companies once treated it like a utility—now, it’s on every CFO’s radar.

“We’re in a period of sustained disruption,” Mordchaev explained in our interview. “And the reality is that global trade won’t stabilize anytime soon. Tariffs are back, CBSA and CBP are cracking down harder, and nearshoring is shaking up supply lanes. Logistics leaders are no longer ops managers. They’re strategic decision-makers.”

This new reality is forcing companies to rethink their hiring strategies. “Ten years ago, it was about lean supply chains. Now it’s about resilient ones,” he added. “And resilience comes from the people who can make high-stakes decisions under pressure.”

While technology plays a role, Mordchaev pointed out to The Globe and Mail that its limits are real. “Software can show you delays. It can’t solve them. That takes judgment, experience, and leadership—and that’s where the right team matters.”

Generalist Recruiters Can’t Do What We Do

Unlike traditional firms that place roles across multiple industries, Logistics Talent Agency focuses exclusively on logistics and supply chain recruitment. Their entire model is built around domain knowledge, deep candidate networks, and an insider’s understanding of the challenges companies are facing.

“We’ve worked in the industry. I come from global trade and compliance,” Mordchaev shared. “We speak the language of logistics. When we talk to candidates, we’re not reading from a script, we’re talking shop.”

This level of fluency is what allows the firm to consistently headhunt top talent, passive candidates who are too busy performing to respond to job board listings or generic recruiter messages.

“If you don’t understand the business, you can’t have meaningful conversations with the people who run it,” Mordchaev said. “That’s where generalists fall short, and it’s why our clients come to us.”

He continued, “We listen. We ask the right questions. And we uncover what companies actually need, not what the job description says, but what’s broken, what’s missing, and what kind of operator it takes to fix it.”

What’s Really Driving Hiring Demand

While many companies focus their attention on VP and C-suite hiring, Mordchaev pointed out that the most dramatic ROI often comes from mid-level operational talent.

“The warehouse manager who reduces damage rates. The customs lead who gets clearance times down by 20%. The logistics analyst who identifies $2 million in annual carrier overcharges. These are the hires that move the needle.”

As freight volatility, labor shortages, and compliance pressures converge, Mordchaev said more businesses are waking up to the fact that logistics recruitment is not an administrative task; it’s a strategic investment.

“The smartest companies aren’t waiting until something breaks,” he said. “They’re building teams that can withstand the pressure now and adapt to whatever’s next.”

Hiring Across the Entire Supply Chain

When asked about the roles in highest demand, Mordchaev noted that the needs vary by industry, but the pattern remains consistent.

The firm regularly recruits for:

  • Logistics Managers & Coordinators

  • Warehouse & Distribution Leads

  • Global Trade & Customs Compliance Directors

  • Transportation & Route Optimization Specialists

  • VPs of Logistics & Chief Supply Chain Officers

  • Cross-Border Ops Experts (United States/Mexico)

“We are helping companies staff entire logistics departments, not just one-off roles,” he said. “Whether it is a food importer, an ecommerce brand, or a freight forwarder, they all need people who can keep things moving under pressure.”

From retail and manufacturing to food distribution and customs brokerage, Logistics Talent Agency works across industries that rely on logistics as a competitive advantage.

Freight, Policy, and People: The New Supply Chain Equation

Throughout our conversation, one theme came up again and again: you can’t separate supply chain performance from the people who run it.

“Between container shortages, rising drayage costs, trade compliance crackdowns, and talent burnout, companies are realizing that their logistics strategy must be built on more than tech and spreadsheets,” Mordchaev emphasized.

He recounted a placement where a single customs expert reduced FDA-bound delays by 30%, freeing up inventory, improving delivery rates, and accelerating revenue recognition. “That kind of operational impact starts with recruitment,” he noted. “And you only get it when you hire people who know this world inside and out.”

As the logistics landscape across North America continues to evolve, one thing is clear: the companies that are winning have invested in their talent, not just their tools.

“We’re not in a stable era,” Mordchaev told The Globe and Mail. Tariffs are changing. Trade routes are shifting. And your logistics team has to be two steps ahead. That’s what we help our clients build: teams that are ready for what’s next.”

Because in a market where freight strategy can make or break a business, the right hire isn’t a luxury. It’s a necessity.

About Logistics Talent Agency

Logistics Talent Agency is North America’s leading recruitment firm focused exclusively on logistics, supply chain, and global trade roles. From logistics coordinators to directors, VPs, and CSCOs, the firm places high-performing talent across the United States, Canada, and Mexico.

Media Contact
Company Name: Logistics Talent Agency
Contact Person: Eden Mordchaev
Email: Send Email
Phone: 2102863124
Address:111 Congress Ave.
City: Austin
State: Texas 78704
Country: United States
Website: http://www.logisticstalentagency.com

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veteran Affairs and Emory University

NEW YORK – June 25th, 2025 – Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.

The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

“With obesity at epidemic levels and no curative therapies available, we believe the VA’s biologic GDNF is potentially a game-changer,” said Eric Weisblum, CEO of Silo Pharma. “We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials.”

“This VA-originated obesity technology has the potential to disrupt a $16 billion market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders,” added Robb Knie, CEO of Hoth Therapeutics. “We are proud to partner with Silo Pharma in an effort to bring this innovation to the public.”

Deal Highlights:

• Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use

• 50/50 joint venture structure with equal equity and governance participation

• Lead indication: Obesity and NAFLD — conditions with prevalence among both civilian and veteran populations

Unmet Need:

Obesity affects over 40% of U.S. adults and is a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care. There are no approved curative biologics targeting the neuroinflammatory root of obesity, a gap that this VA-originated technology is uniquely positioned to fill.

Strategic Alignment:

The partnership leverages:

• The clinical infrastructure and public mission of the VA

• Hoth’s regulatory and development expertise

• Silo’s translational capabilities and capital efficiency

About Silo Pharma

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Source: SILO Pharma Inc.

Contact 800-705-0120

investors@silopharma.com

Media Contact
Company Name: Plato Data Intelligence
Contact Person: Bryan Feinberg
Email: Send Email
Phone: +1551 574-2169
Address:144 E 44th Street
City: New York
State: New York
Country: United States
Website: platodata.io

Orthopedic Power Tools Market Growing at 4.15% CAGR, to Reach USD 2.17 Billion by 2030

“Orthopedic Power Tools Market”
Mordor Intelligence has published a new report on the Orthopedic Power Tools market offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

Mordor Intelligence, in its latest Orthopedic Power Tools Market report, forecasts the market to grow from USD 1.77 billion in 2025 to USD 2.17 billion by 2030, at a CAGR of 4.15%. The orthopedic power tools market refers to the segment of medical devices specifically designed for cutting, drilling, reaming, and screwing during orthopedic surgical procedures such as joint replacement, trauma fixation, and spinal surgeries. These tools are essential in enabling precise and efficient bone operations, improving surgical outcomes, and reducing operating times.

 

Key Trends

The orthopedic power tools market is being shaped by several strong, interrelated trends:

Rising burden of musculoskeletal conditions : The prevalence of osteoarthritis, trauma-related injuries, and other orthopedic conditions is on the rise. This is driving higher volumes of joint replacement and trauma surgeries worldwide, particularly in North America and Europe, resulting in increased demand for precision cutting and drilling tools.

Shift towards battery-powered (cordless) platforms : Battery-powered systems claimed XX.X% of market share in 2024 and are forecast to grow at a X.X% CAGR through 2030. These systems offer greater mobility in operating rooms and are especially suited for ambulatory surgical centers (ASCs), which require compact, lightweight instruments for quick turnaround procedures.

Growth of ambulatory surgical centers : ASCs held X.X% CAGR growth through 2030 as more orthopedic procedures move to outpatient settings. These facilities prefer cordless, single-use instruments to improve efficiency and infection control.

Integration with robotic and navigation systems : Surgeons increasingly demand precision tools compatible with robotics and navigation platforms. This has prompted manufacturers to introduce sensor-equipped, “smart” handpieces that link seamlessly with digital systems.

Preference for sterile, single-use handpieces : With growing concerns around surgical site infection (SSI), there is a rise in the use of single-use handpieces, which are projected to expand at a CAGR of X.X% through 2030. These are especially prevalent in outpatient settings where sterilization logistics pose a challenge.

 

Market Segmentation

Here’s the Market Segmentation for the Orthopaedic Power Tools Market, based solely on the Mordor Intelligence report:

  • By Device Type: The market is categorized into large‑bone power tools (such as saws, reamers, drills), small‑ and medium‑bone instruments, and high‑speed devices. In 2024, large‑bone tools accounted for approximately XX.X% of total revenue. However, high‑speed tools designed for procedures like minimally invasive decompressions and arthroscopy are growing the fastest, recording a projected CAGR of X.X % through 2030.

 

  • By Technology (Power Source): This covers battery‑powered (cordless), electric (corded), and pneumatic-powered systems. As of 2024, battery‑powered platforms dominated with a XX.X % market share and are expected to grow at a X.X % CAGR through 2030. Cordless systems are favoured for their mobility and “plug‑and‑play” ease in compact ORs and ambulatory surgical centres.

 

  • By Usage Modality: The market splits between reusable and single‑use (disposable) systems. Reusable systems continue to lead, holding a XX.X % revenue share in 2024. Nevertheless, single‑use handpieces are gaining traction expanding at about X.X % CAGR through 2030 driven largely by concerns over infection control and the simplicity of disposables in outpatient settings.

 

  • By End‑User: End‑users include hospitals and ambulatory surgical centers (ASCs). Hospitals held approximately XX.0 % of the market in 2024, reflecting their role in complex, high‑volume surgeries. ASCs, however, are expanding faster at a X.X % CAGR due to their increasing preference for fast‑turnover, same‑day orthopaedic procedures.

 

  • By Geography: The market is segmented across North America, Europe, Asia‑Pacific, the Middle East & Africa, and South America. In 2024, North America led with a XX.X % revenue share, while Asia‑Pacific is poised as the fastest-growing region, projected to grow at a X.X% CAGR through 2030

 

Key Players

The report identifies several major players and their competitive positioning within the market:

  • Tryker A leading medical technologies firm known for its extensive orthopedic product portfolio encompassing implants, surgical equipment, navigation systems, and power tools. Stryker’s devices are used globally, supporting procedures ranging from joint replacements to trauma surgeries.

  • Conmed A key player in the orthopedic power tools market, Conmed specializes in a range of surgical instruments including drills, saws, and reamers tailored for orthopedic applications. It maintains a solid presence in both hospital and ASC settings.

  • Zimmer Biomet This company offers a wide spectrum of orthopedic solutions, including implants and power tools for procedures like joint replacements and trauma management. Zimmer Biomet focuses on comprehensive surgical systems and supportive instrumentation.

  • B. Braun Known for its contributions across various medical-device segments, B. Braun provides orthopedic power tools and surgical systems, with distribution reaching hospitals worldwide. Its tools support a broad suite of orthopedic procedures.

  • Medtronic A diversified medical-device leader, Medtronic offers orthopedic power tools as part of its surgical devices division. The company emphasizes integration of innovative systems for surgical precision and performance

 

Conclusion

From USD 1.77 billion in 2025 to an expected USD 2.17 billion by 2030, the orthopedic power tools market is steadily growing at a 4.15% CAGR. Its trajectory is guided by several key forces: a rising musculoskeletal disease burden, demand for streamlined outpatient procedures, and the shift toward smarter, cordless tools suitable for digital operating rooms.

North America remains the dominant region, though Asia-Pacific is set to outpace other regions in growth. The ongoing preference for cordless systems, single-use handpieces, and compatibility with robotic surgical systems underscores a shift toward more nimble, precise, and infection-conscious solutions.

Major incumbents are responding through targeted innovation, often launching battery-operated systems and disposable handpieces that meet ASC needs. For buyers and investors, understanding how these broader healthcare trends outpatient care, digital OR adoption, and aging populations are driving demand will be key to staying ahead in the evolving landscape.

For More Insights: https://www.mordorintelligence.com/industry-reports/orthopedic-power-tools-market?utm_source=abnewswire

 

Industry Related Reports

Powered Surgical Instruments Market: The Orthopedic Power Tools Market Report is segmented by Power Source (Wired-Electric, Battery-Powered (Li-Ion, NiMH), and Others), Product Type (Handpieces, and Others), Application (Orthopedic & Trauma, and Others), End-User (Hospitals, and Others), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market forecasts are provided in terms of value (USD).

 

Surgical Drills Market: The Surgical Drills Market report segments the industry into By Product (Type of Drills, Accessories), By Application (Orthopedic Surgeries, Dental Surgeries, ENT (Ear, Nose, Throat) Surgeries, Other Applications), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

 

Get More Insights: https://www.mordorintelligence.com/industry-reports/surgical-drills-market?utm_source=abnewswire

 

Surgical Equipment Market: The Surgical Equipment Market report segments the industry into By Product (Handheld Devices, Powered and Electrosurgical Devices, Sutures and Staplers), By Application (Obstetrics and Gynecology, Orthopedics, Cardiovascular, Neurology, Plastic and Reconstructive Surgeries, Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, and Others)

 

About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact: media@mordorintelligence.com https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Orthopedic Power Tools Market Growing at 4.15% CAGR, to Reach USD 2.17 Billion by 2030